Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation posted November 12, 2026.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated corporate presentation posted November 12, 2026
- Investor relevance depends on substantive pipeline, clinical, financing or strategic updates in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q4 2026 corporate presentation highlights imdusiran as the lead cHBV asset, with potential Phase 2b development plans under evaluation
- Cash and equivalents of $104.6M as of October 31, 2026, supporting near-term clinical development
- Phase 2a data: 46% of 105 patients achieved functional cure or discontinued NA therapy
- Long-term follow-up: 16 of 18 patients who stopped NA therapy remained off treatment through up to 146+ weeks
- Key risks remain clinical validation, regulatory approval, patent litigation, and cash-resource sufficiency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.